Several reports have been published recently demonstrating a beneficial effect of epidermal
growth factor receptor (EGFR) inhibitors in improving pathologic and behavioral conditions …

Numerous molecular mechanisms are being examined in an attempt to discover disease-
modifying drugs to slow down the underlying neurodegeneration in Alzheimer's disease …

Many researchers are attempting to identify drugs that can be repurposed as effective
therapies for Alzheimer's disease (AD). Several recent studies have highlighted epidermal …

Clinical trials of new drugs for Alzheimer's disease (AD) have ended with disappointing
results, with tremendous resources and time. Repositioning of existing anti-cancer …

Despite all of the progress in understanding its molecular biology and pathogenesis,
glioblastoma (GBM) is one of the most aggressive types of cancers, and without an efficient …

Epidermal growth factor receptor (EGFR) and the mutant EGFRvIII are major focal points in
current concepts of targeted cancer therapy for glioblastoma multiforme (GBM), the most …

Administration of epidermal growth factor receptor (EGFR) inhibitors (eg
AG1478/PD168393) promotes central nervous system (CNS) axon regeneration in vivo by …

Glioblastoma is a particularly resilient cancer, and while therapies may be able to reach the
brain by crossing the blood–brain barrier, they then have to deal with a highly invasive tumor …

Epidermal growth factor receptor (EGFR) plays a pivotal role in early brain development,
although its expression pattern declines in accordance with the maturation of the active …

Cypermethrin is reported to affect astrocytes in rat brain; however, its mechanism of action is
obscure. Here, we observed an increase in apoptosis in the cortical astrocytes upon …